<DOC>
	<DOCNO>NCT00458705</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , doxorubicin hydrochloride liposome dexamethasone , work different way stop growth cancer cell , either kill cell stop dividing . Thalidomide may stop growth cancer cell block blood flow cancer . Giving bortezomib together doxorubicin hydrochloride liposome dexamethasone follow thalidomide , dexamethasone , bortezomib may kill cancer cell . PURPOSE : This phase II trial study side effect well give bortezomib together doxorubicin hydrochloride liposome dexamethasone follow thalidomide dexamethasone without bortezomib work treat patient multiple myeloma .</brief_summary>
	<brief_title>Bortezomib , Doxorubicin Hydrochloride Liposome , Dexamethasone Followed Thalidomide Dexamethasone With Without Bortezomib Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy safety bortezomib , pegylated doxorubicin hydrochloride liposome , dexamethasone follow thalidomide dexamethasone without bortezomib patient symptomatic high-risk primary resistant multiple myeloma . OUTLINE : Patients receive BDD comprise bortezomib IV day 1 , 4 , 8 , 11 ; pegylated doxorubicin hydrochloride liposome IV 60-90 minute day 4 ; oral dexamethasone day 1 , 2 , 4 , 5 , 8 , 9 , 11 , 12 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients achieve response BDD receive oral thalidomide day 1-28 oral dexamethasone day 1-4 , 9-12 , 17-20 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . Patients experience stable progressive disease BDD receive oral thalidomide day 1-28 ; oral dexamethasone day 1 , 2 , 4 , 5 , 8 , 9 , 11 , 12 , 17-21 ; bortezomib IV day 1 , 4 , 8 , 11 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically serologically confirm multiple myeloma meet one follow criterion : Highrisk myeloma , define symptomatic International Staging System ( ISS ) stage 2 3 multiple myeloma Softtissue involvement myeloma form softtissue plasmacytoma Extension plasmacytoma soft tissue Primary resistant myeloma , define unchanged progressive myeloma despite two course standard treatment No ISS stage 1 multiple myeloma without softtissue involvement No smolder myeloma PATIENT CHARACTERISTICS : ECOG performance status 03 Life expectancy &gt; 16 week Absolute granulocyte count ≥ 1,500/mm³ ( unless low granulocyte count due multiple myeloma ) Platelet count ≥ 100,000/mm³ ( unless low platelet count due multiple myeloma ) Bilirubin ≤ 2.0 mg/dL AST ALT &lt; 3 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 3 time ULN LVEF ≥ 50 % MUGA ECHO Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 4 month prior , , 4 week completion study treatment No active thromboembolic disease anticoagulation No active angina myocardial infarction within past 6 month No preexist neuropathy sensory neuropathic pain ≥ grade 2 No concurrent active malignancy nonmelanoma skin cancer carcinoma situ cervix Prior malignancy require antitumor treatment within past 24 month allow Patients history stage I II ( T1a/b ) prostate cancer ( detect incidentally transurethral resection prostate [ TURP ] comprise &lt; 5 % resected tissue ) allow prostatespecific antigen remain normal since TURP No known HIV positivity AIDSrelated illness No medical condition reason , opinion investigator , would preclude study compliance No history hypersensitivity reaction attribute conventional formulation doxorubicin hydrochloride component pegylated doxorubicin hydrochloride liposome , bortezomib , boron , mannitol PRIOR CONCURRENT THERAPY : Prior radiotherapy allow No 2 course prior initial chemotherapy multiple myeloma No prior bortezomib No prior highdose steroid ( include taper ) 1 month duration emergent indication , hypercalcemia lifethreatening lesion ( e.g. , spinal cord compromise ) ( highrisk patient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>